ARCUS BIOSCIENCES INC (RCUS)
US03969F1093 - Common Stock
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
Notable Thursday Option Activity: AMC, HA, RCUS
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences Announces New Employment Inducement Grants
Noteworthy Wednesday Option Activity: GRMN, KODK, RCUS
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Arcus Biosciences Announces New Employment Inducement Grants
Gilead stock downgraded at Truist (NASDAQ:GILD)
Gilead Sciences (GILD) faced a downgrade by Truist Securities due to changes in its cancer development programs conducted with Arcus Biosciences (RCUS). Read more here.
Arcus Biosciences GAAP EPS of -$1.08 misses by $0.06, revenue of $31M beats by $2.7M (NYSE:RCUS)
Arcus Biosciences reports Q4 financial results, with earnings per share missing expectations but revenue beating estimates.
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
Notable Friday Option Activity: KNSL, RCUS, BMBL
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
Commit To Purchase Arcus Biosciences At $15, Earn 33.5% Annualized Using Options
Arcus Biosciences: Did Gilead Sciences overpay for its latest investment? (NYSE:RCUS)
Gilead Sciences' recent investment in Arcus Biosciences raises questions of overpayment, as Wall Street shows skepticism.
Gilead gets FDA okay for faster Yescarta production process (NASDAQ:GILD)
Gilead's (GILD) Kite unit has received FDA approval for faster manufacturing of CAR T-cell therapy Yescarta, reducing turnaround time to 14 days from 16 days. Read more here.
Arcus shares extend gains amid mixed reactions on Gilead stake purchase (NYSE:RCUS)
Arcus Biosciences sees a boost in trading after Gilead Sciences increases stake in the company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today!
Gilead invests $320M in Arcus, expands stake to 33% (NYSE:RCUS)
Arcus Biosciences (RCUS) shares jumped 16% in post-market trading Monday following news that partner Gilead Sciences (GILD) has increased its stake in the compa
Gilead and Arcus Announce Amended Collaboration and Equity Investment
Arcus Biosciences Announces New Employment Inducement Grants
Arcus stock gains on data for Gilead-partnered cancer drug
Arcus Biosciences (RCUS) stock gained after data from a Phase 1b trial for its pancreatic cancer therapy quemliclustat co developed with Gilead (GILD). Read more here.
Notable Two Hundred Day Moving Average Cross - RCUS
Arcus Biosciences Breaks Above 200-Day Moving Average - Bullish for RCUS